Basic Information
| LncRNA/CircRNA Name | THOR |
| Synonyms | Lnc-THOR, ENSG00000226856 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | sorafenib? | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | liver cancer |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, other |
| Sample | HCC tissues and cell lines (HCCLM3 and SMMC7721) |
| Expression Pattern | up-regulated |
| Function Description | Mechanistically, we found ?-catenin as the downstream of THOR in HCC cells. The special ?-catenin inhibitor FH535 abolished the discrepancy in liver CSC proportion and the self-renewal capacity between THOR knockdown HCC cells and control cells, which further confirmed that ?-catenin was required in THOR promoted liver CSCs expansion. Moreover, interference THOR hepatoma cells were more sensitive to sorafenib treatment, indicates that HCC patients with low THOR expression may benefit from sorafenib treatment. |
| Pubmed ID | 30359743 |
| Year | 2019 |
| Title | Long Non-Coding RNA THOR Promotes Liver Cancer Stem Cells Expansion via ?-Catenin Pathway |
External Links
| Links for THOR | GenBank HGNC NONCODE |
| Links for liver cancer | OMIM COSMIC |